Travere Therapeutics, Inc.
TVTXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Travere Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 14 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 22, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Vinva Investment Management Ltd | 2026-03-31 | 15,390 | Not shown | SEC filing |
| Legato Capital Management LLC | 2026-03-31 | 64,110 | $1.9M | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 1,345,111 | $40M | SEC filing |
| Marex Group plc | 2026-03-31 | 18,227 | $542K | SEC filing |
| Palo Alto Investors LP | 2026-03-31 | 230,453 | $6.85M | SEC filing |
| RA CAPITAL MANAGEMENT, L.P. | 2026-03-31 | 746,841 | $22.2M | SEC filing |
| TD Asset Management Inc | 2026-03-31 | 17,534 | $521K | SEC filing |
| Bayforest Capital Ltd | 2026-03-31 | 3,512 | $104K | SEC filing |
| Empowered Funds, LLC | 2026-03-31 | 84,820 | $2.52M | SEC filing |
| True Wealth Design, LLC | 2026-03-31 | 62 | $1.84K | SEC filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2026-03-31 | 790,812 | $23.5M | SEC filing |
| MERCER GLOBAL ADVISORS INC /ADV | 2026-03-31 | 7,218 | $214K | SEC filing |
| SG Americas Securities, LLC | 2026-03-31 | 54,691 | Not shown | SEC filing |
| Park Place Capital Corp | 2026-03-31 | 29 | $862 | SEC filing |
| E Fund Management Co., Ltd. | 2026-03-31 | 19,162 | $569K | SEC filing |
| MPM BIOIMPACT LLC | 2026-03-31 | 1,133,365 | $33.7M | SEC filing |
| GUGGENHEIM CAPITAL LLC | 2026-03-31 | 46,118 | $1.37M | SEC filing |
| STATE OF WISCONSIN INVESTMENT BOARD | 2026-03-31 | 125,879 | $3.74M | SEC filing |
| Elequin Capital, LP | 2026-03-31 | 29 | $862 | SEC filing |
| Woodline Partners LP | 2026-03-31 | 302,666 | $8.99M | SEC filing |
- Each value is checked against Travere Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Travere Therapeutics, Inc.'s share price.
- Value not shown for 1 row: the value per share could not be confirmed against the share prices on file from within three months of the report date.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Travere Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-04-15 · Dube Eric M: Larger than 79 of the 84 other insider sales of Common Stock on file. SEC filing
- 2026-04-14 · REED ELIZABETH E: Larger than 77 of the 84 other insider sales of Common Stock on file. SEC filing
- 2026-04-01 · Dube Eric M: Larger than 76 of the 84 other insider sales of Common Stock on file. SEC filing
- 2026-02-20 · Dube Eric M: Larger than 80 of the 84 other insider sales of Common Stock on file. SEC filing
- 2026-02-03 · Dube Eric M: Larger than 82 of the 84 other insider sales of Common Stock on file. SEC filing
- 2026-01-27 · Dube Eric M: Larger than 78 of the 84 other insider sales of Common Stock on file. SEC filing
- 2025-12-24 · ROTE WILLIAM E.: Larger than 80 of the 84 other insider sales of Common Stock on file. SEC filing
- 2025-11-04 · Calvin Sandra: Larger than 83 of the 84 other insider sales of Common Stock on file. SEC filing
- 2025-10-28 · Dube Eric M: Larger than all 84 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-12 | Coughlin Timothy · Director | Common Stock | S — Open market or private sale | −10,000 | 50.07 | SEC filing |
| 2026-06-12 | Baynes Roy D. · Director | Common Stock | S — Open market or private sale | −4,500 | 50.00 | SEC filing |
| 2026-05-15 | Coughlin Timothy · Director | Common Stock | S — Open market or private sale | −3,250 | 43.49 | SEC filing |
| 2026-05-06 | Dube Eric M · CHIEF EXECUTIVE OFFICER | Common Stock | S — Open market or private sale | −22,500 | 43.95 | SEC filing |
| 2026-05-06 | Inrig Jula · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −311 | 43.95 | SEC filing |
| 2026-05-06 | REED ELIZABETH E · Chief Legal Officer and GC | Common Stock | S — Open market or private sale | −2,076 | 43.95 | SEC filing |
| 2026-05-06 | ROTE WILLIAM E. · Chief Research Officer | Common Stock | S — Open market or private sale | −2,763 | 43.95 | SEC filing |
| 2026-05-06 | Cline Christopher R. · CHIEF FINANCIAL OFFICER | Common Stock | S — Open market or private sale | −310 | 43.95 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-22 | Inrig Jula · CHIEF MEDICAL OFFICER | Common Stock | G — Bona fide gift | −468 | SEC filing |
| 2026-06-12 | Baynes Roy D. · Director | Stock option (right to buy) | M — Exercise or conversion of derivative security | −4,500 | SEC filing |
| 2026-06-12 | Baynes Roy D. · Director | Common Stock | M — Exercise or conversion of derivative security | +4,500 | SEC filing |
| 2026-06-12 | Coughlin Timothy · Director | Common Stock | M — Exercise or conversion of derivative security | +10,000 | SEC filing |
| 2026-06-12 | Coughlin Timothy · Director | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −10,000 | SEC filing |
| 2026-05-19 | Orwin John A · Director | Common Stock | A — Grant, award, or other acquisition | +4,000 | SEC filing |
| 2026-05-19 | LYONS GARY A · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +12,000 | SEC filing |
| 2026-05-19 | Williams Brinkley Ruth · Director | Common Stock | A — Grant, award, or other acquisition | +4,000 | SEC filing |
Showing 8 of 23 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.